Compound News and Research

RSS

Ahead of Nov. elections, Hill GOP shelves 'big-ticket' legislation

After a tumultuous week of party infighting and leadership stumbles, congressional Republicans are focused on calming their divided ranks in the months ahead, mostly by touting proposals that have wide backing within the GOP and shelving any big-ticket legislation for the rest of the year. Comprehensive immigration reform, tax reform, tweaks to the federal health care law -- bipartisan deals on each are probably dead in the water for the rest of this Congress.

19 Feb 2014

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

By 2020, nearly 80 million people are expected to have glaucoma, a disorder of the eye that, if left untreated, can damage the optic nerve and eventually lead to blindness.

19 Feb 2014

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).

18 Feb 2014

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.

18 Feb 2014

First Edition: February 18, 2014

Kaiser Health News staff writer Jay Hancock, working in collaboration with USA Today, reports: "Congratulations. You bought insurance through one of the online Affordable Care Act exchanges, possibly after days or weeks of trying to get the site to work. Don't relax. Joining the plan is only the first challenge. Now you have to understand it. Policies sold through the online portals -- to more than 3 million people so far -- cover essential benefits and put a cap on your out-of-pocket medical costs. But you need to follow the rules" (Hancock, 2/17).

18 Feb 2014

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.

18 Feb 2014

Novel compound appears to protect mice against movement problems associated with PD

Scientists report that they have developed a novel compound that appears to protect mice against developing movement problems associated with Parkinson's disease (PD). The research, which could one day in the future translate into a therapy that could halt the progression of PD and thereby prevent the symptoms of the disease, appears in ACS' Journal of Medicinal Chemistry.

12 Feb 2014

Cedars-Sinai receives $1M grant to study molecular changes in brain due to air pollutants

Researchers at the Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery at Cedars-Sinai will conduct a study to determine if several potentially toxic compounds that exist in polluted air are capable of entering the brain from the bloodstream and causing brain cancer.

12 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).

11 Feb 2014

Viewpoints: The debate at AOL about a baby's medical costs; Gov. Jindal says economy's verdict on health law is not good

Late last week, Tim Armstrong, the chief executive officer of AOL, landed himself in a media firestorm when he held a town hall with employees to explain why he was paring their retirement benefits. After initially blaming Obamacare for driving up the company's health care costs, he pointed the finger at an unlikely target: babies. Specifically, my baby. ... ... She weighed 1 pound, 9 ounces. ... I take issue with how he reduced my daughter to a "distressed baby" who cost the company too much money. How he blamed the saving of her life for his decision to scale back employee benefits. How he exposed the most searing experience of our lives, one that my husband and I still struggle to discuss with anyone but each other, for no other purpose than an absurd justification for corporate cost-cutting (Deanna Fei, 2/9)

11 Feb 2014

Researchers figure out ways to increase anti-cancer activity in broccoli

While researching methods to increase the already well-recognized anti-cancer properties of broccoli, researchers at the University of Illinois also found a way to prolong the vegetable's shelf life.

11 Feb 2014

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).

10 Feb 2014

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.

10 Feb 2014

Viewpoints: Health law distorting--or 'undistorting' the labor market; gas stations should follow CVS' lead; ways to fight heroin

On Wednesday, Douglas Elmendorf, the director of the nonpartisan Congressional Budget Office, said the obvious: losing your job and choosing to work less aren't the same thing.

10 Feb 2014

Scientists develop new approach to design drugs from genome sequence

In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.

10 Feb 2014

Researchers create promising compound for cancer treatment

A promising compound for cancer treatment has been syntesised in a laboratory by an RMIT University researcher during his PhD research.

9 Feb 2014

Proprietary supplement improves cognitive processing speed of older adults

Declines in the underlying brain skills needed to think, remember and learn are normal in aging. In fact, this cognitive decline is a fact of life for most older Americans.

7 Feb 2014

Combination of etoposide with compounds that interfere with cell division improves therapeutic window for cancer treatments

A large part of the effort dedicated to cancer research is directed towards the search for combinations of existing drugs-many of which have already been introduced into clinical practice-that permit higher overall survival rates and improvements in the quality of life of cancer patients.

7 Feb 2014

Surgeons report safer method to replace bone removed from skull after lifesaving brain surgery

Johns Hopkins surgeons report they have devised a better, safer method to replace bone removed from the skull after lifesaving brain surgery. The new technique, they say, appears to result in fewer complications than standard restoration, which has changed little since its development in the 1890s.

4 Feb 2014

Compound News and Research

Ahead of Nov. elections, Hill GOP shelves 'big-ticket' legislation

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

First Edition: February 18, 2014

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

Novel compound appears to protect mice against movement problems associated with PD

Cedars-Sinai receives $1M grant to study molecular changes in brain due to air pollutants

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Omeros announces additional positive data from OMS824 Phase 1 program

Viewpoints: The debate at AOL about a baby's medical costs; Gov. Jindal says economy's verdict on health law is not good

Researchers figure out ways to increase anti-cancer activity in broccoli

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

Viewpoints: Health law distorting--or 'undistorting' the labor market; gas stations should follow CVS' lead; ways to fight heroin

Scientists develop new approach to design drugs from genome sequence

Researchers create promising compound for cancer treatment

Proprietary supplement improves cognitive processing speed of older adults

Combination of etoposide with compounds that interfere with cell division improves therapeutic window for cancer treatments

Surgeons report safer method to replace bone removed from skull after lifesaving brain surgery

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News